India put a partial ban on the drug, touted March 25 by President Trump as a “game changer” in the U.S. response to COVID-19, to maintain an adequate supply for its own citizens.
The country put a total ban on exports on April 4, and in an April 6 news briefing, President Trump said he disagreed with the ban and threatened unspecified “retaliation” against India if it didn’t lift the ban, Business Insider reported.
The Indian government released a statement April 7 that didn’t mention President Trump’s comments but said it was partially lifting the ban in “appropriate quantities.”
Read the full article here.
More articles on pharmacy:
Gilead boosts remdesivir production, now has 1.5M doses
Walgreens adds 6 COVID-19 safety measures to protect workers
2 East Coast pharmacy schools graduating students early to fight COVID-19
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.